70 results on '"Massie, Barry M."'
Search Results
2. The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics
3. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response
4. Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial
5. Depression and Outcome among Veterans with Implantable Cardioverter Defibrillators with or without Cardiac Resynchronization Therapy Capability
6. Relationship between heart rate and mortality and morbidity in the irbesartan patients with heart failure and preserved systolic function trial (I-Preserve)
7. International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial
8. The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial
9. Sex-specific acute heart failure phenotypes and outcomes from PROTECT
10. Clinical Pharmacy Services in Heart Failure: An Opinion Paper from the Heart Failure Society of America and American College of Clinical Pharmacy Cardiology Practice and Research Network
11. Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF
12. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study
13. A double-blind, randomized, parallel, placebo-controlled study examining the effect of cross-linked polyelectrolyte in heart failure patients with chronic kidney disease
14. The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction
15. Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm
16. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE
17. The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment
18. The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment: Findings from PROTECT
19. Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function
20. Rolofylline, an Adenosine A1−Receptor Antagonist, in Acute Heart Failure
21. Is the effect of angiotensin receptor blockade in patients with heart failure modified by treatment with aspirin? The answer is not so clear!
22. Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study
23. Physician-Determined Worsening Heart Failure: A Novel Definition for Early Worsening Heart Failure in Patients Hospitalized for Acute Heart Failure – Association with Signs and Symptoms, Hospitalization Duration, and 60-Day Outcomes
24. Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group
25. Irbesartan for Heart Failure with Preserved Ejection Fraction
26. Treatment of heart failure in the elderly: never say itʼs too late
27. Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction
28. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach
29. Review: available evidence does not support the use of β blockers as first line treatment for hypertension
30. β-Blocker dosing in community-based treatment of heart failure
31. The Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial for advanced heart failure: Study rationale and design
32. Tolerability, Safety, and Efficacy of β-Blockade in Black Patients With Heart Failure in the Community Setting: Insights From a Large Prospective β-Blocker Registry
33. The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart failure Validation Study: Diagnosis and prognosis
34. Heart Failure in Community Practice: Relationship to Age and Sex in a β-Blocker Registry
35. Evidence-based use of levosimendan in different clinical settings
36. Chronic Heart Failure: A Report From the Dartmouth Diastole Discourses
37. Isosorbide dinitrate plus hydralazine was effective for advanced heart failure in black patients
38. β-Blocker therapy for heart failure outside the clinical trial setting: Findings of a community-based registry
39. Cardiac Resynchronization for Heart Failure
40. Renal Function, Digoxin Therapy, and Heart Failure Outcomes: Evidence from the Digoxin Intervention Group Trial
41. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients
42. Incident cases of heart failure in a community cohort: importance and outcomes of patients with preserved systolic function
43. Heart failure: how big is the problem? who are the patients? what does the future hold?
44. Specialty care for heart failure: Does it improve outcomes?
45. Obesity and the Risk of Heart Failure
46. Obesity and Heart Failure - Risk Factor or Mechanism?
47. Short-term Intravenous Milrinone for Acute Exacerbation of Chronic Heart Failure : A Randomized Controlled Trial
48. Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure: Results From the ATLAS Trial
49. Are We Inhibited?: Renal Insufficiency Should Not Preclude the Use of ACE Inhibitors for Patients With Myocardial Infarction and Depressed Left Ventricular Function
50. Evaluating Hypertension Control in a Managed Care Setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.